NEXTBio Capital Management LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0002038158

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q1 2026 · 24 positions · Total reported value $215.37M · Top-10 concentration 71.0% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.5% · 4 new · 4 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -4.2% · vs SPY -6.3% · Prev Value $217.40M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.2% · vs SPY -5.4% · Latest Value $229.71M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q1 2026 13F filing, NEXTBio Capital Management LP disclosed 24 equity positions with a combined reported value of $215.37M. The filing implies a focused portfolio: its ten largest positions account for 71.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2026 were TERN ($31.87M), PTGX ($24.20M), STTK ($20.25M). By sector, the heaviest allocations are Health Care 84.0%, Other 16.0%. Versus the prior quarter, allocation shifted toward Other (+1.7pp) and away from Health Care (-1.7pp).

Versus the prior quarter, NEXTBio Capital Management LP opened 4 new positions, trimmed 4 and fully exited 2, a turnover rate of 38.5% of positions. The portfolio's overlap with the prior quarter was 96% of names.

The largest new positions opened in Q1 2026 were SMMT ($1.70M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2026)

  • SMMT SUMMIT THERAPEUTICS INC · $1.70M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest NEXTBio Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

NEXTBio Capital Management LP, based in Austin, TX, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 22 positions worth $217.40M in total. HoldingsHub carries 3 quarters of its filings (Q4 2025–Q2 2026).

Firm Snapshot

  • Headquarters: AUSTIN, TX, United States
  • SEC registration: 801-136876 (status: Approved), registered 2026-07-23
  • Regulatory AUM (Form ADV): $305.21M as of 2026-07-07
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 6 private funds, of which 1 hedge funds
  • Website: nextbiocapital.com

Portfolio Structure

  • 22 positions · $217.40M reported value (Q2 2026)
  • Top 10 holdings = 77.7% of reported value
  • Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 12.4%
  • Average position size: $9.88M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 new, 7 added, 4 reduced, 5 exited
  • 8 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 84.0%
Other 16.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 604.53K $31.87M 14.80%
14.80%
Add
2 229.62K $24.20M 11.24%
11.24%
Hold
3 3.15M $20.25M 9.40%
9.40%
Hold
4 999.97K $17.84M 8.28%
8.28%
Hold
5 2.02M $11.18M 5.19%
5.19%
Add
6 126.08K $10.97M 5.09%
5.09%
Add
7 183.22K $10.65M 4.95%
4.95%
Hold
8 82.69K $10.31M 4.79%
4.79%
Hold
9 426.74K $8.34M 3.87%
3.87%
Add
10 1.33M $7.40M 3.44%
3.44%
Add
11 1.31M $6.93M 3.22%
3.22%
Hold
12 372.86K $6.85M 3.18%
3.18%
Hold
13 523.62K $6.63M 3.08%
3.08%
Reduce
14 133.24K $6.42M 2.98%
2.98%
Add
15 95.22K $5.53M 2.57%
2.57%
Hold
16 131.19K $5.05M 2.35%
2.35%
Add
17 848.20K $4.49M 2.08%
2.08%
Reduce
18 184.06K $4.23M 1.97%
1.97%
Reduce
19 149.59K $3.98M 1.85%
1.85%
Hold
20 183.36K $3.45M 1.60%
1.60%
Add
21 52.66K $3.37M 1.56%
1.56%
Add
22 131.80K $2.65M 1.23%
1.23%
Hold
23 89.72K $1.70M 0.79%
0.79%
New
24 157.83K $1.07M 0.50%
0.50%
Hold

FAQ

What did NEXTBio Capital Management LP buy in 2026-Q1?

In its 2026-Q1 13F filing, NEXTBio Capital Management LP reported 24 equity positions worth $215.37M in aggregate; its largest disclosed positions were TERN ($31.87M), PTGX ($24.20M), STTK ($20.25M).

How large is NEXTBio Capital Management LP's portfolio?

NEXTBio Capital Management LP reported $215.37M of long equity holdings across 24 positions as of 2026-Q1. Top-10 holdings account for 71.0% of reported value.

What is NEXTBio Capital Management LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/nextbio-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →